Short answer
Corcept Therapeutics Inc (CORT) filed an 8-K current report with the SEC on July 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure), Item 2.02 (Results of Operations and Financial Condition). Corcept announced financial results for the quarter ended June 30, 2026.
Corcept Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Corcept announced financial results for the quarter ended June 30, 2026
- Exhibit 99.1 contains the detailed results and corporate update
- Investor focus: operating performance and any changes to the company’s business outlook
Item 7.01 · Regulation FD Disclosure
- Q2 2026 financial results and corporate update announced for quarter ended June 30, 2026
- Exhibit 99.1 contains the detailed earnings figures and operational developments
- Results announcement provides investors an update on Corcept’s financial performance and business progress
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $256.1M, up 32% YoY, driven by $47.6M Lifyorli launch revenue alongside $208.6M Korlym revenue
- 2026 revenue guidance raised to $1.1B-$1.2B, signaling confidence in accelerating oncology demand and Cushing’s syndrome prescriptions
- Net income $43.0M, up from $35.1M, despite operating expenses rising to $214.8M from $167.8M for Lifyorli commercialization
- Lifyorli reached over 1,300 treated patients after March FDA approval, with NCCN preferred-regimen inclusion supporting adoption
- Relacorilant Cushing’s NDA resubmitted, with FDA decision expected December 17, 2026, creating a key regulatory catalyst
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Corcept Therapeutics Inc 8-K filings
Get the next CORT 8-K as it lands
Follow CORT for push alerts, or ask the research agent what this filing means.